About Us Our BioBank Platform Technology Our Drug Programmes News Contact us Founders INVESTORS NEWS Synairgen was founded by Professors Donna Davies, Ratko Djukanovic, and Stephen Holgate who continue to play an active role in Synairgen. Synairgen plc Registered in England and Wales No. 5233429 Registered office Mailpoint 810, Level F, South Block, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK

About Us Our BioBank Platform Technology Our Drug Programmes News Contact us Advisers INVESTORS NEWS Nominated adviser and joint broker Joint broker Auditors Registrars Solicitors Financial PR Nominated adviser and joint broker finnCap One Bartholomew Close London EC1A 7BL Tel: +44 (0) 20 7220 0500 www.finncap.com Joint broker Numis Securities Limited 10 Paternoster Square London EC4M 7LT Tel: +44 (0) 20 7260 1000 www.numis.com Auditors BDO LLP Level 12 Thames Tower Station Road Reading RG1 1LX Tel: +44(0) 118 925 4400 www.bdo.co.uk Registrars Link Market Services Limited 10th Floor Central Square 29 Wellington Street Leeds LS1 4DL By phone – UK – Tel: 0371 664 0300 , from overseas call +44 (0) 371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls from outside the United Kingdom will be charged at the applicable international rate. We are open 9.00am to 5.30pm Monday – Friday, excluding public holidays in England and Wales. By email – enquiries@linkgroup.co.uk Solicitors Fieldfisher Riverbank House 2 Swan Lane London EC4R 3TT Tel: +44 (0) 20 7861 4000 www.fieldfisher.com/en Financial PR Consilium Strategic Communications 41 Lothbury London EC2R 7HG Tel: +44 (0) 20 3709 5701 www.consilium-comms.com Synairgen plc Registered in England and Wales No. 5233429 Registered office Mailpoint 810, Level F, South Block, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK

About Us Our BioBank Platform Technology Our Drug Programmes News Contact us Glossary INVESTORS NEWS This Glossary is intended to assist readers when referring to technical language used in our materials. The definitions represent the meanings understood and shared by Synairgen and the wider scientific community. A B C D E F H I L M N P R S T U V W Synairgen plc Registered in England and Wales No. 5233429 Registered office Mailpoint 810, Level F, South Block, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK

About Us Our BioBank Platform Technology Our Drug Programmes News Contact us Major Shareholders INVESTORS NEWS Shareholders with interests of over 3% (Significant Shareholders), as advised to the Company, are listed to the right. In so far as the Company is aware, the percentage of the Company’s issued share capital that is not in public hands is 18.1%, which comprises the holding of Polygon Global Partners LLP and the directors’ beneficial holdings of 2.5%. Name of shareholder Number of ordinary shares % of share capital Polygon Global Partners LLP Polar Capital LLP 31,350,000 15,706,535 15.6% 7.8% Synairgen plc Registered in England and Wales No. 5233429 Registered office Mailpoint 810, Level F, South Block, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK